Preclinical evidence toward the use of ketamine for recombinant tissue-type plasminogen activator-mediated thrombolysis under anesthesia or sedation.

Le 02 Nov 2021

Auteur : Gakuba C, Gauberti M, Mazighi M, Defer G, Hanouz JL, Vivien D

Année : 2011

Journal : Stroke 1524-4628

PubMed Id : 21817137

Endovascular treatment of ischemic stroke usually involves recombinant tissue-type plasminogen activator (rtPA)-mediated thrombolysis in anesthetized patients. Paradoxically, differential influences of anesthetic agents on thrombolysis outcome remain unknown.